Alexion Pharmaceuticals (ALXN) : Rhenman Partners Asset Management Ab scooped up 102,082 additional shares in Alexion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 223,082 shares of Alexion Pharmaceuticals which is valued at $30,709,468.Alexion Pharmaceuticals makes up approximately 4.91% of Rhenman Partners Asset Management Ab’s portfolio.
Other Hedge Funds, Including , Evercore Wealth Management reduced its stake in ALXN by selling 102 shares or 6.17% in the most recent quarter. The Hedge Fund company now holds 1,550 shares of ALXN which is valued at $213,373. Alexion Pharmaceuticals makes up approx 0.01% of Evercore Wealth Management’s portfolio.Magee Thomson Investment Partners reduced its stake in ALXN by selling 4,540 shares or 10.04% in the most recent quarter. The Hedge Fund company now holds 40,670 shares of ALXN which is valued at $5,116,286. Alexion Pharmaceuticals makes up approx 1.70% of Magee Thomson Investment Partners’s portfolio.Nn Investment Partners Holdings N.v. reduced its stake in ALXN by selling 38,714 shares or 55.65% in the most recent quarter. The Hedge Fund company now holds 30,850 shares of ALXN which is valued at $3,809,050. Alexion Pharmaceuticals makes up approx 0.04% of Nn Investment Partners Holdings N.v.’s portfolio.Factory Mutual Insurance Co reduced its stake in ALXN by selling 4,000 shares or 14.81% in the most recent quarter. The Hedge Fund company now holds 23,000 shares of ALXN which is valued at $2,839,810. Alexion Pharmaceuticals makes up approx 0.04% of Factory Mutual Insurance Co’s portfolio.
Alexion Pharmaceuticals closed down -2.23 points or -1.62% at $135.43 with 17,08,000 shares getting traded on Thursday. Post opening the session at $138.18, the shares hit an intraday low of $135.205 and an intraday high of $138.4 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .Shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight” and Lowered the Price Target to $ 150 from a previous price target of $165 .RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.